Press Releases

Date Title and Summary
Toggle Summary Survey Confirms the CyberKnife(R) System as the Only Extracranial Radiosurgery Device in Widespread Use
SUNNYVALE, Calif., March 19 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY - News), a global leader in the field of radiosurgery, announced today the results of an independent survey that confirms that the CyberKnife® Robotic Radiosurgery System dominates the field of extracranial
Toggle Summary Summit Cancer Center-Boise Treats Its First Cancer Patients Using the Accuray Radixact™ System
Freestanding Center is First in the Western U.S. to Treat Patients with this "Smart" Radiation Therapy Delivery System with Fully-Integrated Treatment Planning and Data Management Systems SUNNYVALE, Calif. , Aug. 17, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) and the Summit Cancer
Toggle Summary Substantial Clinical Evidence and Adoption Presented at Accuray's TomoTherapy® Asia Pacific Users' Meeting 2012
Fifth Users' Meeting Highlights Efficacy of TomoTherapy® Treatment System and Widespread Acceptance Across the Region SUNNYVALE, Calif. , Oct. 26, 2012 /PRNewswire/ --   Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, showcased new clinical research on its TomoTherapy ®
Toggle Summary Study Shows CyberKnife® System Provides Long-Lasting Pain Relief for Trigeminal Neuralgia Patients
CyberKnife Frameless Radiosurgery Offers a Precise and Non-Invasive Technique with Clinical Outcomes Similar to Gamma Knife Frame-Based Invasive Radiosurgery SUNNYVALE, Calif. , Jan. 29, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a study of 138 patients
Toggle Summary Study Highlights CyberKnife Stereotactic Body Radiotherapy (SBRT): Noninvasive Brachytherapy-like Treatment for Prostate Cancer
Data provides new support for efficacy and toxicity benefits of non-invasively delivering High Dose Rate Brachytherapy dosing to patients with prostate cancer SUNNYVALE, Calif. , Jan. 9, 2012 /PRNewswire/ --   Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today
Toggle Summary Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors
CyberKnife System Broadens Range of Lung Cancer Patients Treatable with SBRT   SUNNYVALE, Calif. , Jan. 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today publication of a study demonstrating the benefits of the CyberKnife® Robotic
Toggle Summary Studies Support Use of the Accuray TomoTherapy® System for Advanced Rectal Cancer to Improve Treatment Efficacy and Reduce Side Effects
SUNNYVALE, Calif. , Feb. 5, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that two new studies demonstrate the benefits of the TomoTherapy ® System  in the treatment of advanced rectal cancer. Radiotherapy, with or without chemotherapy, followed by surgery is the
Toggle Summary Studies Support Growing Use of the Accuray TomoTherapy® System for Breast Cancer to Improve Tumor Control with Reduced Toxicities
Additional Data Demonstrate Accuray TomoTherapy and CyberKnife® Systems Provide Precise Dose Delivery and Tumor Management SUNNYVALE, Calif. , Sept. 18, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that studies presented at the 56th Annual American Society for Radiation
Toggle Summary Stanford University Medical Center to Acquire Second Accuray CyberKnife® M6™ System
New System will be Used to Treat Diseases in the Brain and Base of the Skull SUNNYVALE, Calif. , Dec. 4, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Stanford University Medical Center has selected a second CyberKnife ® M6™ System to expand access to precise
Toggle Summary Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
Prior Studies Demonstrate Frequency of Prostate Motion, Supporting Need for the CyberKnife System's Real-Time Tracking to Spare Surrounding Sensitive Structures SUNNYVALE, Calif ., March 31 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery,

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.